(VIANEWS) – BanColombia S.A. (CIB), Halozyme Therapeutics (HALO), Banco Latinoamericano de Comercio Exterior, S.A. (BLX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BanColombia S.A. (CIB)
42.6% sales growth and 16.3% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.21.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 5.03. Meaning, the purchaser of the share is investing $5.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.3%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 27, 2024, the estimated forward annual dividend rate is 3.4 and the estimated forward annual dividend yield is 10.88%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 1.4% and a drop 7.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 21.09T for the twelve trailing months.
Volume
Today’s last reported volume for BanColombia S.A. is 226607 which is 5.28% below its average volume of 239256.
2. Halozyme Therapeutics (HALO)
33.5% sales growth and 153.16% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.58.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 21.7. Meaning, the purchaser of the share is investing $21.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 153.16%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 33.3% and 56.1%, respectively.
Sales Growth
Halozyme Therapeutics’s sales growth is 20.1% for the present quarter and 33.5% for the next.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $55.99 at 20:22 EST, below its 52-week high of $57.09 and way higher than its 52-week low of $32.83.
3. Banco Latinoamericano de Comercio Exterior, S.A. (BLX)
22.7% sales growth and 16.19% return on equity
Banco Latinoamericano de Comercio Exterior, S.A., a multinational bank, primarily engages in the financing of foreign trade in Latin America and the Caribbean. The company operates through two segments, Commercial and Treasury. It offers short and medium-term bilateral, structured and syndicated credits, and loan commitments; financial guarantee contracts, such as issued and confirmed letters of credit, and stand-by letters of credit; and guarantees covering commercial risk and other assets, as well as co-financing arrangements, underwriting of syndicated credit facilities, structured trade financing in the form of factoring and vendor financing, and financial leasing. The company also provides treasury solutions, which include term deposits and private placements. It primarily serves financial institutions, corporations, and sovereigns and state-owned entities. The company was formerly known as Banco Latinoamericano de Exportaciones, S.A. and changed its name to Banco Latinoamericano de Comercio Exterior, S.A. in June 2009. Banco Latinoamericano de Comercio Exterior, S.A. was founded in 1977 and is headquartered in Panama City, the Republic of Panama.
Earnings Per Share
As for profitability, Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months EPS of $5.28.
PE Ratio
Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months price to earnings ratio of 5.39. Meaning, the purchaser of the share is investing $5.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.19%.
4. Vertex (VERX)
13.8% sales growth and 3.26% return on equity
Vertex, Inc. provides tax technology solutions for corporations in retail, leasing, communication, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also offers implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Vertex has a trailing twelve months EPS of $0.05.
PE Ratio
Vertex has a trailing twelve months price to earnings ratio of 724.2. Meaning, the purchaser of the share is investing $724.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.26%.
Previous days news about Vertex(VERX)
- According to Zacks on Monday, 19 August, "Since the start of this year, CRSP received approval for its Vertex Pharmaceuticals (VRTX Quick QuoteVRTX – Free Report) -partnered one-shot gene therapy Casgevy in two blood disorders, namely sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), in the United States and Europe. ", "In March 2023, CRISPR signed a new deal with Vertex to develop hypoimmune cell therapies for type I diabetes (T1D)."
5. Sapiens International Corporation N.V. (SPNS)
8.3% sales growth and 15.74% return on equity
Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa. The company offers Sapiens CoreSuite and Sapiens IDITSuite for personal, commercial, and specialty lines, as well as reinsurance and workers' compensation; and Sapiens CoreSuite, Sapiens UnderwritingPro, Sapiens ApplicationPro, Sapiens IllustrationPro, and Sapiens ConsolidationMaster for life, pension, and annuities. It also provides Sapiens DigitalSuite for insurance customers, agents, brokers, risk managers, customer groups and third-party service providers; Sapiens AgentConnect and Sapiens CustomerConnect portals; Sapiens Intelligence, an analytics platform; Sapiens IntelligencePro, a comprehensive BI solution with pre-configured reports, dashboards, and scorecards; and Sapiens Advanced Analytics, which uses AI and Machine Learning to generate actionable insights based on different models across the insurance value chain. In addition, the company offers Sapiens ReinsuranceMaster, Sapiens ReinsurancePro, and Sapiens Reinsurance GO reinsurance solutions; and Sapiens Platform, Sapiens CoreSuite, Sapiens PolicyPro, and Sapiens ClaimsPro, as well as Sapiens PolicyGo, Sapiens ClaimsGo, and Sapiens Connect for workers' compensation. Further, it provides financial and compliance solutions, which comprise Sapiens FinancialPro, Sapiens Financial GO, Sapiens StatementPro, Sapiens CheckPro, and Sapiens Reporting Tools; and Sapiens Decision, an enterprise-scale platform that enables institutions to centrally author, store, and manage various organizational business logics. Additionally, the company offers tailor-made solutions based on its Sapiens eMerge platform; and program delivery, business, and managed services. It markets and sells its products and services through direct and partner sales. The company was founded in 1982 and is headquartered in Holon, Israel.
Earnings Per Share
As for profitability, Sapiens International Corporation N.V. has a trailing twelve months EPS of $1.23.
PE Ratio
Sapiens International Corporation N.V. has a trailing twelve months price to earnings ratio of 29.37. Meaning, the purchaser of the share is investing $29.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.74%.
Yearly Top and Bottom Value
Sapiens International Corporation N.V.’s stock is valued at $36.13 at 20:22 EST, way below its 52-week high of $41.22 and way above its 52-week low of $24.39.
Sales Growth
Sapiens International Corporation N.V.’s sales growth for the next quarter is 8.3%.
6. Alaska Air Group (ALK)
6.9% sales growth and 5.5% return on equity
Alaska Air Group, Inc., through its subsidiaries, provides passenger and cargo air transportation services. The company operates through three segments: Mainline, Regional, and Horizon. It has a network of approximately 1,300 daily flights to 115 destinations across the United States, Mexico, Canada, and Costa Rica. The company was founded in 1932 and is based in Seattle, Washington.
Earnings Per Share
As for profitability, Alaska Air Group has a trailing twelve months EPS of $1.76.
PE Ratio
Alaska Air Group has a trailing twelve months price to earnings ratio of 19.11. Meaning, the purchaser of the share is investing $19.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.5%.
